Literature DB >> 24591178

Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.

Olesia Lisova1, Laurent Belkadi, Hugues Bedouelle.   

Abstract

Dengue fever is the most important vector-borne viral disease. Four serotypes of dengue virus, DENV1 to DENV4, coexist. Secondary infection by a different serotype is a risk factor for severe dengue. Monoclonal antibody mAb4E11 neutralizes the four serotypes of DENV with varying efficacies by recognizing an epitope located within domain-III (ED3) of the viral envelope (E) protein. To better understand the cross-reactivities between mAb4E11 and the four serotypes of DENV, we constructed mutations in both Fab4E11 fragment and ED3, and we searched for indirect interactions in the crystal structures of the four complexes. According to the serotype, 7 to 12 interactions are mediated by one water molecule, 1 to 10 by two water molecules, and several of these interactions are conserved between serotypes. Most interfacial water molecules make hydrogen bonds with both antibody and antigen. Some residues or atomic groups are engaged in both direct and water-mediated interactions. The doubly-indirect interactions are more numerous in the complex of lowest affinity. The third complementarity determining region of the light chain (L-CDR3) of mAb4E11 does not contact ED3. The structures and double-mutant thermodynamic cycles showed that the effects of (hyper)-mutations in L-CDR3 on affinity were caused by conformational changes and indirect interactions with ED3 through other CDRs. Exchanges of residues between ED3 serotypes showed that their effects on affinity were context dependent. Thus, conformational changes, structural context, and indirect interactions should be included when studying cross-reactivity between antibodies and different serotypes of viral antigens for a better design of diagnostics, vaccine, and therapeutic tools against DENV and other Flaviviruses.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cross-reactivity; dengue virus; flavivirus; indirect interactions; neutralizing antibody; serotype; structure; water molecules

Mesh:

Substances:

Year:  2014        PMID: 24591178     DOI: 10.1002/jmr.2352

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  6 in total

1.  Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.

Authors:  Julia C Frei; Margaret Kielian; Jonathan R Lai
Journal:  Virology       Date:  2015-09-02       Impact factor: 3.616

2.  Antibody Binding Modulates Conformational Exchange in Domain III of Dengue Virus E Protein.

Authors:  Adolfo H Moraes; Luca Simonelli; Mattia Pedotti; Fabio C L Almeida; Luca Varani; Ana P Valente
Journal:  J Virol       Date:  2015-12-04       Impact factor: 5.103

Review 3.  The Evolution of Molecular Recognition: From Antibodies to Molecularly Imprinted Polymers (MIPs) as Artificial Counterpart.

Authors:  Ortensia Ilaria Parisi; Fabrizio Francomano; Marco Dattilo; Francesco Patitucci; Sabrina Prete; Fabio Amone; Francesco Puoci
Journal:  J Funct Biomater       Date:  2022-01-28

Review 4.  Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections.

Authors:  Kuan-Meng Soo; Bahariah Khalid; Siew-Mooi Ching; Hui-Yee Chee
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

5.  Characterization and epitope mapping of Dengue virus type 1 specific monoclonal antibodies.

Authors:  Wen-Hung Chen; Feng-Pai Chou; Yu-Kuo Wang; Sheng-Cih Huang; Chuan-Hung Cheng; Tung-Kung Wu
Journal:  Virol J       Date:  2017-10-02       Impact factor: 4.099

6.  Structural basis for cross-reactivity and conformation fluctuation of the major beech pollen allergen Fag s 1.

Authors:  Adolfo H Moraes; Claudia Asam; Fabio C L Almeida; Michael Wallner; Fatima Ferreira; Ana Paula Valente
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.